Chiltern International, a global CRO based in the U.K., has appointed Dr. Manuela Niewel as medical director and Lisa Bull as director of strategic partnerships.

Niewel is a medical oncologist with more than 20 years experience in clinical research in oncology and other major therapeutic areas. As medical director, Niewelwill serve as a therapeutic expert in the oncology area in the medical department and will be field-based in Munich, Germany.

“I am extremely pleased to have Manuela’s strong expertise in our medical department as it will provide our clients with a broader oncology experience to help them overcome the complexities often found in oncology trials,” said Aize Smink, COO of Chiltern. “In previous roles, Manuela served as senior medical director where she was responsible for phase I-III oncology trials and has led clinical research teams for both pharmaceutical and clinical research companies.”

Bulljoins Chiltern with more than 20 years experience in the pharmaceutical and CRO industries. She is field-based in the U.K. and a holds a BA degree in Business Studies from U.K.’s Westminster University.

“It gives me great pleasure to welcome Lisa Bull as director of strategic partnerships,” said Stuart McGuire, vice president of global business development, Chiltern. “Lisa has a thorough understanding of clinical development in multiple therapeutic areas and geographies, as well as a strong track record in establishing long standing and successful partnerships.”